SecBot SecBot

CANF

Can-Fite BioPharma Ltd.
NYSE· Pharmaceutical Preparations· Inc. L3· CIK 0001536196 Biotech & Drug Discovery
$1.72 −0.06 (−3.37%)
Oct 26 4:00 PM ET · prev $1.78
Market cap
$5.5M
Nano cap
Median target
$8.00
+365% · range $8.00–8.00
1 year
−81.7%
from $9.40 · Oct 27
30 days
−22.9%
from $2.23
52-week range
$1.72–9.40
at the low
Avg volume 20D
70.5K
Oct 26 spike 856.5K
Short interest
🔒 Subscribers only
Insider net
$0
no open-market trades · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
27
analyzed by SecBot
SecBot read BEARISH 12 reports · 90 days
Balance 4 bearish · 3 bullish · 2 mixed · 3 neutral oldest → newest, height = score
Avg score ·High conf. 6/12
Strongest BEARISH Can-Fite BioPharma's F-3 shelf registration (File No. 333-298625) became effective on October 9, 2026. This…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.

  • InstitutionsMIXED

    Q2 2026: 0 added (0 new), 1 trimmed or exited.

  • TrendDOWNTREND

    28% below its 50-day average. New closing low $1.72 on Oct 26.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
WELLS FARGO & COMPANY/MNTRIM59$175.00

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

last action Jul 2026
12-month targets · 1 analysts

Price is below the lowest target. Median implies +365%.Targets as of Oct 27, 2026.

Recent actions
DateFirmActionRating
Jul 2, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy
May 13, 2026D. Boral Capital
UPGRADE
UPGRADEBuy
May 12, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Sep 8, 2026
Earnings
Can-Fite Reports Q2 2026 Financial Results and Ongoing Clinical Progress Highlighting Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study
RAMAT GAN, Israel, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company developing…
Sep 2, 2026
Announcement
Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds
RAMAT GAN, Israel, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF) (“Can-Fite” or the “Company”), a…
Sep 2, 2026
Announcement
Can-Fite Reports Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study
Company plans to advance the interim analysis of its Phase III Namodenoson study in advanced hepatocellular carcinoma
Jul 20, 2026
Press release
Can-Fite Positive Phase 2a Pancreatic Cancer Study Data Accepted for Presentation at ESMO Congress 2026, One of the World's Premier Scientific Meetings in Oncology
Predominantly third-line pancreatic cancer patients demonstrated durable survival despite advanced disease; patient who received Namodenoson as…
Jul 6, 2026
Earnings
Can-Fite Achieves Key Pivotal Phase 3 Psoriasis Milestone with Completion of Patient Enrolment for the Interim Analysis: Data Expected Q4 2026/Q1 2027
Interim analysis to be conducted under an FDA- and EMA-agreed protocol

Insider ledger

Form 4
$0
open-market buys or sells · 12 mo
DateInsiderTypeValue
Jun 4, 2026
Farbstein Motti
CEO, CFO and COO
AWARD24,000 sh
Jun 4, 2026
Fishman Pnina
Chief Scientific Officer
AWARD24,000 sh

Earnings setup

Estimates
PeriodEPS est.Range30D rev.Revenue
Current Q———$0.00
Next Q———$0.00
Current FY-$2.04-$2.04–-$2.04-200.0%$404.0K
Next FY-$0.91-$0.91–-$0.91-237.0%$404.0K
Reddit

Fresh Reddit data

The last 24 hours of Reddit activity are for subscribers.

Subscribe for Full Access
Recent comments
r/pennystocks1d ago
Fresh comment, for subscribers
All social signals and their track records

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 26, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Oct 13, 2026 SEC
Can-Fite BioPharma's F-3 shelf registration (File No. 333-298625) became effective on October 9, 2026. This allows the…
EFFECT — Impact 5/10
Oct 13, 2026 SEC
Can-Fite BioPharma Ltd.'s F-3 shelf registration (File No. 333-299160) became effective on October 9, 2026. This…
EFFECT — Impact 5/10
Sep 8, 2026 Earnings
Can-Fite Reports Q2 2026 Financial Results and Ongoing Clinical Progress Highlighting Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study
RAMAT GAN, Israel, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF)
Sep 2, 2026 Press
Can-Fite BioPharma announced a warrant exercise agreement to raise ~$4.0M gross proceeds by immediately exercising…
Impact 6/10
Jun 30, 2026 Inst.
WELLS FARGO & COMPANY/MN — TRIM
59 shares ($175.00)
Jun 17, 2026 Press
Can-Fite BioPharma announced its participation in the BIO International Convention 2026 (June 22-25) to conduct…
Impact 3/10
Jun 4, 2026 Insider
Farbstein Motti was granted 24,000 shares
CEO, CFO and COO

SecBot reports

27 filings · 6 press releases · 9 bullish · 3 bearish · 3 mixed · 12 neutral
All CANF filing & press-release reports (33)